Q1 Earnings Forecast for SERA Issued By William Blair

Sera Prognostics, Inc. (NASDAQ:SERA) – Equities research analysts at William Blair issued their Q1 2026 EPS estimates for shares of Sera Prognostics in a research note issued on Thursday, May 8th. William Blair analyst A. Brackmann forecasts that the company will post earnings per share of ($0.23) for the quarter. The consensus estimate for Sera Prognostics’ current full-year earnings is ($0.96) per share. William Blair also issued estimates for Sera Prognostics’ Q2 2026 earnings at ($0.23) EPS, Q3 2026 earnings at ($0.23) EPS, Q4 2026 earnings at ($0.23) EPS and FY2026 earnings at ($0.92) EPS.

Sera Prognostics (NASDAQ:SERA) last posted its earnings results on Wednesday, May 14th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.04. The firm had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.06 million.

Sera Prognostics Trading Up 1.3%

Shares of NASDAQ SERA opened at $2.35 on Monday. The stock has a 50 day simple moving average of $3.40 and a 200-day simple moving average of $5.44. The company has a market cap of $88.51 million, a PE ratio of -2.37 and a beta of 0.99. Sera Prognostics has a 12-month low of $2.10 and a 12-month high of $9.91.

Institutional Trading of Sera Prognostics

Several hedge funds have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets bought a new position in shares of Sera Prognostics in the fourth quarter worth $28,000. XTX Topco Ltd bought a new position in Sera Prognostics in the 1st quarter valued at about $39,000. Price T Rowe Associates Inc. MD acquired a new position in Sera Prognostics during the 4th quarter valued at about $93,000. Gotham Asset Management LLC bought a new stake in shares of Sera Prognostics during the 4th quarter worth about $96,000. Finally, Walleye Capital LLC bought a new stake in shares of Sera Prognostics during the 4th quarter worth about $98,000. Institutional investors own 54.64% of the company’s stock.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.